Astria Therapeutics (NASDAQ:ATXS) Stock Price Passes Above Fifty Day Moving Average - What's Next?

Key Points

• Astria Therapeutics' stock price recently crossed above its 50-day moving average of $6.26, reaching a high of $6.80 during trading.
• Analysts have set a consensus rating of "Buy" for Astria Therapeutics, with an average price target of $29.00, while JMP Securities raised their target price to $26.00.
• Institutional investors hold 98.98% of Astria Therapeutics' stock, with notable increases in stakes from firms such as JPMorgan Chase and Wells Fargo.

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $6.26 and traded as high as $6.80. Astria Therapeutics shares last traded at $6.30, with a volume of 224,693 shares traded.

Analyst Ratings Changes

ATXS has been the subject of several recent analyst reports. JMP Securities upped their price objective on Astria Therapeutics from $25.00 to $26.00 and gave the stock a "market outperform" rating in a research report on Wednesday, August 13th. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Wednesday, August 13th. Citigroup reaffirmed an "outperform" rating on shares of Astria Therapeutics in a report on Wednesday, August 13th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $47.00 target price on shares of Astria Therapeutics in a report on Wednesday, May 14th. One analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. Based on data from MarketBeat.com, Astria Therapeutics has a consensus rating of "Buy" and a consensus price target of $29.00.

Astria Therapeutics Stock Down 3.4%

The company has a market cap of $370.21 million, a price-to-earnings ratio of -3.28 and a beta of 0.48. The firm has a 50 day moving average price of $6.31 and a two-hundred day moving average price of $5.70.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.04. On average, equities analysts expect that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current year.

Institutional Investors Weigh In On Astria Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Farther Finance Advisors LLC grew its stake in Astria Therapeutics by 185.8% during the second quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 3,557 shares during the period. GAMMA Investing LLC grew its stake in Astria Therapeutics by 1,127.4% during the first quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company's stock worth $46,000 after purchasing an additional 7,971 shares during the period. Brooklyn Investment Group grew its stake in Astria Therapeutics by 1,079.6% during the first quarter. Brooklyn Investment Group now owns 8,694 shares of the biotechnology company's stock worth $46,000 after purchasing an additional 7,957 shares during the period. Tower Research Capital LLC TRC boosted its holdings in Astria Therapeutics by 109.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock worth $47,000 after acquiring an additional 2,766 shares in the last quarter. Finally, BNP Paribas Financial Markets bought a new position in Astria Therapeutics in the fourth quarter worth approximately $50,000. Institutional investors and hedge funds own 98.98% of the company's stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.